ELARIS

Dexocort-6 is a trusted formulation of Deflazacort 6 mg, offering effective anti-inflammatory and immunosuppressive action for a wide range of chronic inflammatory and autoimmune conditions. It is especially useful in managing disorders like rheumatoid arthritis, asthma, allergic reactions, and muscular dystrophies.

Fenclav 625 is a powerful combination of Amoxicillin (500 mg), a broad-spectrum penicillin antibiotic, and Clavulanic Acid (125 mg), a β-lactamase inhibitor that protects Amoxicillin from enzymatic degradation. This synergistic pairing extends antimicrobial coverage against β-lactamase-producing bacteria.

Fenclav 228.5 contains Amoxicillin 200 mg and Clavulanic Acid 28.5 mg per 5 mL, formulated for safe and effective use in infants and toddlers. It provides targeted action against resistant organisms in conditions like lower respiratory tract infections, otitis media, and soft tissue infections.

Fenclav 457 is a pediatric formulation combining Amoxicillin 400 mg and Clavulanic Acid 57 mg per 5 mL, designed for broad-spectrum bacterial coverage in children. It is highly effective in treating pediatric respiratory tract infections, otitis media, pharyngitis, tonsillitis, and skin infections caused by β-lactamase-producing pathogens.

Fenxone 1 gm contains Ceftriaxone, a third-generation cephalosporin antibiotic with broad-spectrum bactericidal activity. It works by inhibiting bacterial cell wall synthesis and is highly effective against a wide range of Gram-positive and Gram-negative organisms, including resistant strains.

Fenxone-S is a synergistic combination of Ceftriaxone, a third-generation cephalosporin, and Sulbactam, a β-lactamase inhibitor that enhances Ceftriaxone’s activity against resistant pathogens. This powerful pairing provides extended-spectrum coverage against multi-drug resistant Gram-positive and Gram-negative bacteria.

Fenzopan 40 contains Pantoprazole 40 mg, a proton pump inhibitor (PPI) that provides powerful and long-lasting acid suppression by irreversibly inhibiting the H⁺/K⁺-ATPase enzyme in gastric parietal cells. It is highly effective in the treatment of GERD, peptic ulcers, erosive esophagitis, and Zollinger-Ellison syndrome. With rapid onset and once-daily dosing,

Levoritz-M combines Montelukast (a leukotriene receptor antagonist) and Levocetirizine (a third-generation antihistamine) to offer dual-action relief from allergic rhinitis, seasonal allergies, and asthma-related symptoms. While Levocetirizine effectively blocks H1 receptors to reduce sneezing, itching, and runny nose.

Levoritz-M Syrup is a pediatric-friendly combination of Montelukast Sodium and Levocetirizine Dihydrochloride, offering comprehensive relief from allergic rhinitis, chronic urticaria, and mild asthma symptoms in children. Levocetirizine acts as a potent, non-sedating antihistamine that controls nasal congestion, sneezing, and itching.

Toffy-D Syrup is a balanced triple-action formula combining Phenylephrine (5 mg/5 mL), a selective α₁-adrenergic agonist that reduces nasal congestion; Chlorpheniramine Maleate (2 mg/5 mL), an antihistamine that relieves sneezing, rhinorrhea, and allergic symptoms; and Dextromethorphan Hydrobromide (10 mg/5 mL), a centrally acting antitussive that suppresses dry, irritating cough.